ClinicalTrials.gg
CompletedNCT02072824Updated Jan 20, 2021Results posted

A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

A Phase 3 interventional study of Pregabalin Dose Level 1 and Pregabalin Dose Level 2 in Partial Onset Seizures, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 72 sites in 23 countries. Open to participants aged 1 Month to 3 Years. Per ClinicalTrials.gov, last updated 2021-01-20.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
1 Month to 3 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Epilepsy by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Epilepsy · Viatris Inc..

Enrollment
9th of 15
175 · median 219
Started
2014
the only one that year
Phase 3
12 of 19
none open now
Registered
19th of 19
by date

Among the 19 studies in Epilepsy by Viatris Inc., this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2014, is one of 12 in phase 3, and was the 19th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

None of the 19 studies in Epilepsy by Viatris Inc. is open now. The open studies under Epilepsy, anywhere →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 1 Month to 3 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Epilepsy by Viatris Inc. as a file.
02

Study summary

This study is designed to evaluate the effectiveness of 2 doses of pregabalin to reduce seizure frequency as an add on therapy in pediatric subjects 1 month to \<4 years of age with refractory partial onset seizures. It is hypothesized that both doses of pregabalin will demonstrate superior efficacy when compared to placebo by reducing the partial onset seizure frequency and that pregabalin will be safe and well tolerated.

03

Conditions studied

  • Partial Onset Seizures

Browse trials for

Keywords

  • Partial Onset Seizures
  • Epilepsy
  • Safety
  • Efficacy
  • Tolerability
  • Pregabalin
  • Lyrica
  • Adjunctive treatment
  • Placebo controlled
  • blinded
  • Eligibility Criteria
04

Who can participate

Ages eligible
1 Month to 3 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have 3 partial onset seizures in the month prior to screening.
  • Subject must have 2 partial onset seizures during the 48 hour baseline phase.
  • Signed .
  • On 1-3 stable anti-epileptic drugs at screening.

Exclusion criteria

Exclusion Criteria:

  • Primary generalized seizures including clonic, tonic, clonic-tonic, absence, febrile seizures, and infantile spasms.
  • Lennox-Gasteau, BECTS, and Dravet's syndrome.
  • Status epliepticus within 1 year of screening.
  • Any change in AED regimen with 7 days of screening.
  • Progressive structural central nervous system (CNS) lesion or a progressive encephalopathy.
  • Progressive errors of metabolism.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Study Drug Level 1

    Drug: Pregabalin Dose Level 1

  • Experimental
    Study Drug Level 2

    Drug: Pregabalin Dose Level 2

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugPregabalin Dose Level 1

    Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase

  • DrugPregabalin Dose Level 2

    Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase

  • DrugPlacebo

    Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase

06

What researchers measure

Primary outcomes

  1. Log Transformed 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase

    All partial onset seizures experienced during treatment phase were recorded by central reader during the 48 to 72 hour video-electroencephalogram (EEG). Double Blind 24 hour EEG seizure rate for all partial onset seizures = (\[Number of seizures in double blind 48 to 72 hour EEG assessment\] divided by \[number of hours of video-EEG monitoring\])\*24. The EEG assessment was done at the end of the fixed dose treatment. For log-transformation, the quantity 1 was added to the double blind 24 hour EEG seizure rate for all participants to account for any possible "0" seizure incidence. This resulted in final calculation as: log transformed (double-blind 24-hour EEG seizure rate + 1).

    Time frame: Day 1 up to Day 14

Secondary outcomes

  1. Responder Rate: Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase

    Responder Rate was defined as percentage of participants who had a 50% or greater reduction from baseline in 24-hour seizure rate during the double-blind treatment phase. Double Blind 24 hour EEG seizure rate for all partial onset seizures = (\[Number of seizures in double blind 48 to 72 hour EEG assessment\] divided by \[number of hours of video-EEG monitoring\])\*24. The EEG assessment was done at the end of the fixed dose treatment.

    Time frame: Day 1 up to Day 14

Other outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events which occurred between first dose of study drug and up to end of study (up to Day 25) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.

    Time frame: Day 1 up to End of study (EOS) (maximum Day 25)

  2. Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events which occurred between first dose of study drug and up to end of study (up to Day 25) that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to drug was assessed by the investigator. AEs included both serious and non-serious adverse events.

    Time frame: Day 1 up to EOS (maximum Day 25)

  3. Number of Adverse Events by Severity

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories a) mild: AEs does not interfere with participant's usual function b) moderate: AEs interferes to some extent with participant's usual function c) severe: AEs interferes significantly with participant's usual function.

    Time frame: Day 1 up to EOS (maximum Day 25)

  4. Number of Participants With Laboratory Test Abnormalities

    Abnormality Criteria: hemoglobin,hematocrit,red blood cells(RBC)count:\<0.8\*lower limit of normal\[LLN\],platelets:\<0.5\*LLN/\>1.75\*upper limit of normal\[ULN\]; leukocytes:\<0.6\*LLN/\>1.5\*ULN; lymphocytes,neutrophils, total protein,albumin, tetraiodothyronine,thyroid stimulating hormone:\<0.8\*LLN/\>1.2\*ULN; basophils,eosinophils,monocytes:\>1.2\*ULN; prothrombin \[PT\],PT international ratio:\>1.1\*ULN; aspartate aminotransferase,alanine aminotransferase,alkaline phosphatase,gamma glutamyl transferase:\>0.3\*ULN; bilirubin:\>1.5\*ULN; blood urea nitrogen,creatinine, cholesterol,triglycerides:\>1.3\*ULN; sodium: \<0.95\*LLN/\>1.05\*ULN; potassium,chloride,calcium,bicarbonate:\<0.9\*LLN/\>1.1\*ULN; glucose fasting:\<0.6\*LLN/\>1.5\*ULN; creatine kinase:\>2\*ULN;urine glucose,ketone,protein:\>=1;urine WBC,RBC:\>= 20/High Power Field\[HPF\]; urine casts,hyaline casts:\>1/Low Power Field; urine bacteria:\>20/HPF.

    Time frame: From Baseline up to EOS (maximum Day 25)

  5. Number of Participants With Vital Signs Abnormalities

    Criteria for abnormalities in vital signs included: sitting/supine systolic blood pressure (SBP) values: maximum increase and decrease of greater than or equal to (\>=) 30 millimeter of mercury (mmHg) from baseline; sitting/supine diastolic blood pressure (DBP) value: maximum increase and decrease of \>=20 mmHg from baseline.

    Time frame: From Baseline (BL) up to EOS (maximum Day 25)

  6. Percentage of Participants With Abnormal Physical Examination Findings at Screening and End of Study

    Physical examinations evaluated the following body systems/organs: abdomen; ears; extremities; eyes; general appearance; head; heart; lungs; lymph nodes; mouth; musculoskeletal; nose; skin and throat. Abnormalities in physical examination were based on investigator's discretion.

    Time frame: Screening and EOS (maximum Day 25)

  7. Percentage of Participants With Abnormal Neurological Examination Findings at Baseline and End of Study

    Neurological examinations included: coordination; cranial nerve function (CNF); gait and station; level of consciousness (LOC); lower and upper extremity sensation; muscle strength; muscle tone; nystagmus; reflexes and speech. Abnormalities in neurological examination were based on investigator's discretion and also, some components of the neurological examination were not done for certain participants due to participant age or significant developmental impairment. Only those categories of neurological examination in which at least 10% of participants had an abnormality in any treatment group at any time point were reported in this outcome measure.

    Time frame: Baseline (BL) and EOS (maximum Day 25)

  8. Number of Participants With Electrocardiogram (ECG) Abnormalities

    Criteria for abnormalities in ECG findings: 1) Time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS complex): \>=140 milliseconds (msec); 2) The interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval): \>=200 msec; 3) Time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula (QTCF interval): absolute value 450 to \<480 msec, 480 to \<500 msec, \>=500 msec; 4) Maximum QT interval: \>=500 msec; 5) Maximum QTCB interval (Bazett's correction): 450 to\< 480 msec, 480 to \<500 msec, \>=500 msec. Only those categories of ECG abnormalities in which participants were found abnormal (maximum QTCB interval 450-\<480 msec), were reported in this outcome measure.

    Time frame: From screening up to EOS (maximum Day 25)

07

Results

Posted Oct 9, 2018

Participant flow

Participant flow — Overall Study
MilestonePregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlacebo
Started713470
Completed693367
Not completed213
Withdrew: Insufficient clinical response101
Withdrew: No longer willing to participate101
Withdrew: Medication error010
Withdrew: Adverse event001

Outcome measures

PrimaryLog Transformed 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase

All partial onset seizures experienced during treatment phase were recorded by central reader during the 48 to 72 hour video-electroencephalogram (EEG). Double Blind 24 hour EEG seizure rate for all partial onset seizures = (\[Number of seizures in double blind 48 to 72 hour EEG assessment\] divided by \[number of hours of video-EEG monitoring\])\*24. The EEG assessment was done at the end of the fixed dose treatment. For log-transformation, the quantity 1 was added to the double blind 24 hour EEG seizure rate for all participants to account for any possible "0" seizure incidence. This resulted in final calculation as: log transformed (double-blind 24-hour EEG seizure rate + 1).

Time frame:
Day 1 up to Day 14
Reported as:
Least squares mean · seizures per 24 hours
Log Transformed 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase
seizures per 24 hoursPregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlacebo
Log Transformed 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase1.69 ± 0.1151.15 ± 0.1631.58 ± 0.129
Statistical analysis
  • Pregabalin 7 mg/kg/Day or 6 mg/kg/Day vs Placebo · ANCOVA · p = 0.4606 · Least square mean difference: 0.11 · 95% CI -0.19 to 0.42
  • Pregabalin 14 mg/kg/Day or 12 mg/kg/Day vs Placebo · ANCOVA · p = 0.0223 · Least square mean difference: -0.43 · 95% CI -0.80 to -0.06
SecondaryResponder Rate: Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase

Responder Rate was defined as percentage of participants who had a 50% or greater reduction from baseline in 24-hour seizure rate during the double-blind treatment phase. Double Blind 24 hour EEG seizure rate for all partial onset seizures = (\[Number of seizures in double blind 48 to 72 hour EEG assessment\] divided by \[number of hours of video-EEG monitoring\])\*24. The EEG assessment was done at the end of the fixed dose treatment.

Time frame:
Day 1 up to Day 14
Reported as:
Number · percentage of participants
Responder Rate: Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase
percentage of participantsPregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlacebo
Responder Rate: Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase30.5153.5741.51
Statistical analysis
  • Pregabalin 7 mg/kg/Day or 6 mg/kg/Day vs Placebo · Regression, Logistic · p = 0.2418 · Odds ratio (or): 0.625 · 95% CI 0.284 to 1.373
  • Pregabalin 14 mg/kg/Day or 12 mg/kg/Day vs Placebo · Regression, Logistic · p = 0.3050 · Odds ratio (or): 1.622 · 95% CI 0.644 to 4.086
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events which occurred between first dose of study drug and up to end of study (up to Day 25) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.

Time frame:
Day 1 up to End of study (EOS) (maximum Day 25)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlacebo
AEs321738
SAEs014
Other pre-specifiedNumber of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events which occurred between first dose of study drug and up to end of study (up to Day 25) that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to drug was assessed by the investigator. AEs included both serious and non-serious adverse events.

Time frame:
Day 1 up to EOS (maximum Day 25)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlacebo
AEs15813
SAEs001
Other pre-specifiedNumber of Adverse Events by Severity

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories a) mild: AEs does not interfere with participant's usual function b) moderate: AEs interferes to some extent with participant's usual function c) severe: AEs interferes significantly with participant's usual function.

Time frame:
Day 1 up to EOS (maximum Day 25)
Reported as:
Number · events
Number of Adverse Events by Severity
eventsPregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlacebo
Mild602367
Moderate31319
Severe000
Other pre-specifiedNumber of Participants With Laboratory Test Abnormalities

Abnormality Criteria: hemoglobin,hematocrit,red blood cells(RBC)count:\<0.8\*lower limit of normal\[LLN\],platelets:\<0.5\*LLN/\>1.75\*upper limit of normal\[ULN\]; leukocytes:\<0.6\*LLN/\>1.5\*ULN; lymphocytes,neutrophils, total protein,albumin, tetraiodothyronine,thyroid stimulating hormone:\<0.8\*LLN/\>1.2\*ULN; basophils,eosinophils,monocytes:\>1.2\*ULN; prothrombin \[PT\],PT international ratio:\>1.1\*ULN; aspartate aminotransferase,alanine aminotransferase,alkaline phosphatase,gamma glutamyl transferase:\>0.3\*ULN; bilirubin:\>1.5\*ULN; blood urea nitrogen,creatinine, cholesterol,triglycerides:\>1.3\*ULN; sodium: \<0.95\*LLN/\>1.05\*ULN; potassium,chloride,calcium,bicarbonate:\<0.9\*LLN/\>1.1\*ULN; glucose fasting:\<0.6\*LLN/\>1.5\*ULN; creatine kinase:\>2\*ULN;urine glucose,ketone,protein:\>=1;urine WBC,RBC:\>= 20/High Power Field\[HPF\]; urine casts,hyaline casts:\>1/Low Power Field; urine bacteria:\>20/HPF.

Time frame:
From Baseline up to EOS (maximum Day 25)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities
ParticipantsPregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlacebo
Number of Participants With Laboratory Test Abnormalities652961
Other pre-specifiedNumber of Participants With Vital Signs Abnormalities

Criteria for abnormalities in vital signs included: sitting/supine systolic blood pressure (SBP) values: maximum increase and decrease of greater than or equal to (\>=) 30 millimeter of mercury (mmHg) from baseline; sitting/supine diastolic blood pressure (DBP) value: maximum increase and decrease of \>=20 mmHg from baseline.

Time frame:
From Baseline (BL) up to EOS (maximum Day 25)
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Abnormalities
ParticipantsPregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlacebo
Maximum Increase from BL(>=30):sitting/supine SBP201
Maximum Increase from BL(>=20):sitting/supine DBP713
Maximum Decrease from BL(>=30):sitting/supine SBP101
Maximum Decrease from BL(>=20):sitting/supine DBP221
Other pre-specifiedPercentage of Participants With Abnormal Physical Examination Findings at Screening and End of Study

Physical examinations evaluated the following body systems/organs: abdomen; ears; extremities; eyes; general appearance; head; heart; lungs; lymph nodes; mouth; musculoskeletal; nose; skin and throat. Abnormalities in physical examination were based on investigator's discretion.

Time frame:
Screening and EOS (maximum Day 25)
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormal Physical Examination Findings at Screening and End of Study
percentage of participantsPregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlacebo
Abdomen: Screening4.25.92.9
Abdomen: EOS4.25.91.4
Ears: Screening1.401.4
Ears: EOS1.401.4
Extremities: Screening14.126.515.7
Extremities: EOS14.126.518.8
Eyes: Screening9.920.617.1
Eyes: EOS9.920.618.8
General appearance: Screening15.526.515.7
General appearance: EOS15.523.515.9
Head: Screening31.047.131.4
Head: EOS33.847.131.9
Heart: Screening1.48.84.3
Heart: EOS1.45.94.3
Lungs: Screening2.88.84.3
Lungs: EOS2.88.85.8
Lymph nodes: Screening08.80
Lymph nodes: EOS02.90
Mouth: Screening9.92.95.7
Mouth: EOS7.12.95.8
Musculoskeletal: Screening31.038.235.7
Musculoskeletal: EOS33.838.237.7
Nose: Screening02.90
Nose: EOS005.8
Skin: Screening9.914.721.4
Skin: EOS8.514.721.7
Throat: Screening1.42.90
Throat: EOS05.92.9
Other pre-specifiedPercentage of Participants With Abnormal Neurological Examination Findings at Baseline and End of Study

Neurological examinations included: coordination; cranial nerve function (CNF); gait and station; level of consciousness (LOC); lower and upper extremity sensation; muscle strength; muscle tone; nystagmus; reflexes and speech. Abnormalities in neurological examination were based on investigator's discretion and also, some components of the neurological examination were not done for certain participants due to participant age or significant developmental impairment. Only those categories of neurological examination in which at least 10% of participants had an abnormality in any treatment group at any time point were reported in this outcome measure.

Time frame:
Baseline (BL) and EOS (maximum Day 25)
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormal Neurological Examination Findings at Baseline and End of Study
percentage of participantsPregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlacebo
Coordination- left hand movement (BL)1.411.88.6
Coordination-left hand movement (EOS)1.48.810.1
Coordination- right hand movement (EOS)2.85.910.1
Coordination- romberg test (BL)2.88.810.0
Coordination- romberg test (EOS)2.85.911.6
CNF- left eye visual field (BL)12.78.810.0
CNF- left eye visual field (EOS)12.78.810.1
CNF: right eye visual field (BL)12.75.910.0
CNF: right eye visual field (EOS)12.75.910.1
CNF: left fundoscopic exam (BL)12.726.512.9
CNF: left fundoscopic exam (EOS)12.723.514.5
CNF: right fundoscopic exam (BL)11.320.614.3
CNF: right fundoscopic exam (EOS)11.317.614.5
CNF: left visual acuity (BL)11.311.812.9
CNF: left visual acuity (EOS)11.311.813.0
CNF: right visual acuity (BL)11.311.811.4
CNF: right visual acuity (EOS)11.311.811.6
CNF: finger tracking (BL)22.526.524.3
CNF: finger tracking (EOS)21.123.526.1
CNF: swallowing (BL)14.114.714.3
CNF: swallowing (EOS)14.114.714.5
CNF:Left shoulder,head turn strength (BL)11.32.97.1
CNF: Left shoulder shrug,head turn strength (EOS)11.32.910.1
Gait and station - gait (BL)52.150.045.7
Gait and station - gait (EOS)52.152.946.4
Level of consciousness (BL)5.620.65.7
Level of consciousness (EOS)7.020.62.9
Muscle strength -lower extremities (BL)49.358.851.4
Muscle strength -lower extremities (EOS)49.358.853.6
Muscle strength - upper extremities (BL)47.958.850.0
Muscle strength - upper extremities (EOS)49.358.852.2
Muscle strength - trunk (BL)43.738.244.3
Muscle strength - trunk (EOS)39.438.242.0
Muscle tone - lower extremities (BL)64.373.563.8
Muscle tone - lower extremities (EOS)64.873.566.2
Muscle tone - upper extremities (BL)64.873.563.8
Muscle tone - upper extremities (EOS)64.873.566.2
Nystagmus - horizontal (BL)9.911.87.1
Nystagmus - horizontal (EOS)8.511.85.8
Reflexes - left ankle (BL)46.552.947.1
Reflexes - left ankle (EOS)46.552.946.4
Reflexes - right ankle (BL)46.558.847.1
Reflexes - right ankle (EOS)45.158.846.4
Reflexes - left babinski (BL)42.347.147.1
Reflexes - left babinski (EOS)40.847.147.8
Reflexes - right babinski (BL)42.355.950.0
Reflexes - right babinski (EOS)40.855.950.7
Reflexes - left biceps (BL)47.952.950.0
Reflexes - left biceps (EOS)47.952.949.3
Reflexes - right biceps (BL)46.558.852.9
Reflexes - right biceps (EOS)46.558.852.2
Reflexes - left brachioradialis (BL)45.152.948.6
Reflexes - left brachioradialis (EOS)45.152.947.8
Reflexes - right brachioradialis (BL)43.758.850.0
Reflexes - right brachioradialis (EOS)43.758.850.7
Reflexes - left knee (BL)53.555.957.1
Reflexes - left knee (EOS)52.158.856.5
Reflexes - right knee (BL)52.161.861.4
Reflexes - right knee (EOS)50.764.759.4
Reflexes - left triceps (BL)46.552.945.7
Reflexes - left triceps (EOS)46.552.944.9
Reflexes - right triceps (BL)45.158.848.6
Reflexes - right triceps (EOS)45.158.847.8
Speech - articulation (BL)53.547.145.7
Speech - articulation (EOS)54.944.147.8
Speech - language (BL)69.076.565.7
Speech - language (EOS)69.073.566.7
Other pre-specifiedNumber of Participants With Electrocardiogram (ECG) Abnormalities

Criteria for abnormalities in ECG findings: 1) Time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS complex): \>=140 milliseconds (msec); 2) The interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval): \>=200 msec; 3) Time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula (QTCF interval): absolute value 450 to \<480 msec, 480 to \<500 msec, \>=500 msec; 4) Maximum QT interval: \>=500 msec; 5) Maximum QTCB interval (Bazett's correction): 450 to\< 480 msec, 480 to \<500 msec, \>=500 msec. Only those categories of ECG abnormalities in which participants were found abnormal (maximum QTCB interval 450-\<480 msec), were reported in this outcome measure.

Time frame:
From screening up to EOS (maximum Day 25)
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Abnormalities
ParticipantsPregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlacebo
Number of Participants With Electrocardiogram (ECG) Abnormalities020

Adverse events

Collected over Day 1 up to End of Study (maximum Day 25). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin 7 mg/kg/Day or 6 mg/kg/Day0/71 (0%)0/71 (0%)32/71 (45.1%)
Pregabalin 14 mg/kg/Day or 12 mg/kg/Day0/34 (0%)1/34 (2.9%)16/34 (47.1%)
Placebo0/70 (0%)4/70 (5.7%)37/70 (52.9%)
Most frequent serious events
Most frequent serious events
EventPregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlacebo
PneumoniaInfections and infestations0/711/340/70
RhinitisInfections and infestations0/710/341/70
DehydrationMetabolism and nutrition disorders0/710/341/70
SeizureNervous system disorders0/710/341/70
ChokingRespiratory, thoracic and mediastinal disorders0/710/341/70
Most frequent other events
Showing 10 of 80
Most frequent other events
EventPregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlacebo
SomnolenceNervous system disorders8/716/344/70
Upper respiratory tract infectionInfections and infestations5/714/348/70
VomitingGastrointestinal disorders1/710/346/70
PyrexiaGeneral disorders4/712/344/70
NasopharyngitisInfections and infestations1/712/343/70
PneumoniaInfections and infestations1/712/340/70
Viral infectionInfections and infestations2/712/342/70
SeizureNervous system disorders1/712/343/70
Decreased appetiteMetabolism and nutrition disorders0/710/343/70
CoughRespiratory, thoracic and mediastinal disorders1/710/343/70

Baseline characteristics

Safety population included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(months)Pregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlaceboTotal
Mean27.5 ± 12.728.5 ± 12.528.8 ± 12.628.2 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlaceboTotal
Female26143272
Male452038103
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlaceboTotal
Asian23101952
White472449120
Other1023
Weight
Weight(kilogram)Pregabalin 7 mg/kg/Day or 6 mg/kg/DayPregabalin 14 mg/kg/Day or 12 mg/kg/DayPlaceboTotal
Mean11.7 ± 3.511.4 ± 3.411.4 ± 3.111.5 ± 3.3
08

Study locations

72 sites
  • Pediatric Epilepsy Center of Central Florida
    Orlando, Florida 32819, United States
  • Pediatric Neurology, PA
    Orlando, Florida 32819, United States
  • Pediatric Epilepsy & Neurology Specialists, PA
    Tampa, Florida 33609, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Road Runner Research, Ltd.
    San Antonio, Texas 78249, United States
  • GU Republican Scientific and Practical Center Mother and Child
    Minsk, 220053, Belarus
  • UZ Brussel
    Brussels, Bruxelles Capitale 1090, Belgium
  • University Clinical Centre of the Republic of Srpska
    Banja Luka, 78000, Bosnia and Herzegovina
  • UMHAT Dr. Georgi Stranski Ltd.
    Pleven, 5800, Bulgaria
  • UMHAT "Sveti Georgi" Ltd.
    Plovdiv, 4002, Bulgaria
  • The First Bethune Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Children's Hospital of Fudan University
    Shanghai, Shanghai 201102, China
  • Beijing Children's Hospital
    Beijing, 100045, China
  • Hopital Raymond Poincare
    Garches, 92380, France
  • Universitaetsklinikum Jena
    Jena, Thueringen 07747, Germany
  • University General Hospital Attikon
    Athens, 12462, Greece
  • General Hospital of Thessaloniki Ippokratio
    Thessaloniki, 54642, Greece
  • Dr. Kenessey Albert Korhaz es Rendelointezet
    Balassagyarmat, H-2660, Hungary
  • Szent János Kórház es Észak Budai Egyesitett Kórházak
    Budapest, H-1023, Hungary
  • Szent Margit Kórház
    Budapest, H-1032, Hungary
  • Semmelweis Egyetem, I. Sz. Gyermekgyogyaszati Klinika
    Budapest, H-1083, Hungary
  • Magyarorszagi Reformatus Egyhaz Bethesda Gyermekkorhaz, Gyermekneurologia
    Budapest, H-1146, Hungary
  • Debreceni Egyetem Klinikai Központ
    Debrecen, H-4032, Hungary
  • Pharmacy of The E. Wolfson Medical Center
    Holon, 5810001, Israel
  • The E. Wolfson Medical Center
    Holon, 5810001, Israel
  • Pharmacy of Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • American University of Beirut Medical Center
    Beirut, Lebanon
  • Saint George Hospital - University Medical Center
    Beirut, Lebanon
  • Hospital Raja Perempuan Zainab II
    Kota Bharu, Kelantan 15586, Malaysia
  • Cebu Doctors' University Hospital
    Cebu City, Cebu 6000, Philippines
  • Perpetual Succour Hospital
    Cebu City, Cebu 6000, Philippines
  • Manila Doctors Hospital
    Manila, 1000, Philippines
  • Metropolitan Medical Center
    Manila, 1003, Philippines
  • University of Santo Tomas Hospital
    Manila, 1008, Philippines
  • St. Luke's Medical Center
    Quezon City, 1102, Philippines
  • Philippine Children's Medical Center
    Quezon City, 1105, Philippines
  • Centrul Medical Unirea
    Bucuresti, 013766, Romania
  • Spitalul Clinic de Urgente pentru Copii "Sf. Maria"
    Iasi, 700309, Romania
  • Nizhmedklinika
    Nizhniy Novgorod, Nizhegorodskaya Oblast 603159, Russian Federation
  • Perm State Medical University n. a. acad. E.A. Vagner
    Perm, Permskiy KRAY 614000, Russian Federation
  • FSFEI HE N.I. Pirogov RNRMU of Minzdrav of Russia
    Moscow, 117997, Russian Federation
  • FSFEI HE N.I. Pirogov RNRMU of Minzdrav of Russia
    Moscow, 125412, Russian Federation
  • Perm State Medical University n. a. acad. E.A. Vagner
    Perm, 614990, Russian Federation
  • St. Petersburg State Pediatric Medical University
    Saint Petersburg, 194100, Russian Federation
  • "Baltiyskaya Medicyna" LLC
    Saint Petersburg, 194356, Russian Federation
  • LLC Medical Technologies
    Saint-Petersburg, 191025, Russian Federation
  • LLC Medical Technologies
    Saint-Petersburg, 192148, Russian Federation
  • RSBHI Smolensk Regional Clinical Hospital
    Smolensk, 214018, Russian Federation
  • SHI Ulyanovsk Regional Children's Clinical Hospital n. a. Y.F.Goryachev
    Ulyanovsk, 432011, Russian Federation
  • SHI Central Clinical Medical Unit
    Ulyanovsk, 432026, Russian Federation
  • SHI Central Clinical Medical Unit
    Ulyanovsk, 432045, Russian Federation
  • MAI Children's City Clinical Hospital 9
    Yekaterinburg, 620134, Russian Federation
  • Institute for Child and Youth Healthcare of Vojvodina
    Novi Sad, Vojvodina 21000, Serbia
  • Mother and Child Healthcare Institute Dr Vukan Cupic
    Belgrade, 11000, Serbia
  • University Children's Hospital Belgrade
    Belgrade, 11000, Serbia
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
  • Chang Gung Memorial Hospital- Kaohsiung branch
    Kaohsiung, 833, Taiwan
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Siriraj Hospital, Faculty of Medicine, Mahidol University
    Bangkoknoi, Bangkok 10700, Thailand
  • Phramongkutklao Hospital
    Ratchathevee, Bangkok 10400, Thailand
  • Izmir Tepecik Training and Research Hospital
    Izmir, Konak 35120, Turkey
  • Eskisehir Osmangazi Universitesi Tip Fakultesi
    Eskisehir, 26480, Turkey
  • Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi
    Trabzon, 61080, Turkey
  • Komunalnyi zaklad "Dnipropetrovska dytiacha miska klinichna likarnia #5"
    Dnipro, 49027, Ukraine
  • Komunalnyi zaklad "Dnipropetrovska oblasna dytiacha klinichna likarnia"
    Dnipro, 49100, Ukraine
  • Ivano-Frankivska oblasna dytiacha klinichna likarnia
    Ivano-Frankivsk, 76018, Ukraine
  • DZ "Ukrainskyi medychnyi tsentr reabilitatsii ditei z orhanichnym urazhenniam
    Kyiv, 04209, Ukraine
  • Oblasnyi klinichnyi tsentr neirokhirurhii ta nevrolohii,viddilennia neirokhirurhii #2
    Uzhgorod, 88018, Ukraine
09

References and documents

Publications

  • Mann D, Antinew J, Knapp L, Almas M, Liu J, Scavone J, Yang R, Modequillo M, Makedonska I, Ortiz M, Kyrychenko A, Nordli D, Farkas V, Farkas MK; A0081042 study group. Pregabalin adjunctive therapy for focal onset seizures in children 1 month to <4 years of age: A double-blind, placebo-controlled, video-electroencephalographic trial. Epilepsia. 2020 Apr;61(4):617-626. doi: 10.1111/epi.16466. Epub 2020 Mar 18. PubMed 32189338 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Mar 2018, 41 months.

Results were first posted in Oct 2018, 6 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 41 months is below that.

Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2014
First posted
Feb 27, 2014
StartActual
Sep 16, 2014
Primary completionActual
Mar 13, 2018
CompletionActual
Mar 13, 2018
Results first posted
Oct 9, 2018
Last update
Jan 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02072824
Responsible party
Sponsor
First posted
Feb 27, 2014
Start date
Sep 16, 2014
Primary completion
Mar 13, 2018
Completion
Mar 13, 2018
Results posted
Oct 9, 2018
Last update
Jan 20, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion